{"success":true,"data":{"pressRelease":{"id":"132553","rtpr_id":"nGNX9Rd6Vp","ticker":"SABS","exchange":"NASDAQ","all_tickers":["SABS","SABSW"],"title":"SAB BIO to Participate in Upcoming Investor Conferences","author":"Globe Newswire","published_at":"2026-09-01T12:30:00.637Z","article_body":"MIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:\nSABS\n(https://www.globenewswire.com/Tracker?data=gn9wlpBP8jVtZmDbRGypmYKJvtq6y1SPPPzWSZf7SJELoOqAJZAK-2vbrfKiPuTjI5M1VX8d569HzTmthbM8n8pUfznUJNSKZwW2LWH1mSQpEfj8lvby_V6cJ0taDVhXfs94rMC9ywfhBNY5eSJxkkPK7yZEccANfcZXUia1RJAE_ewrvVTKoecpq3EjYzUuEcpZIbGLLOscqVNYc46eo44c4M8eyqwSRyzbrrHwxVxoz6etCB5yC13-a-lHvE-3)),\na clinical-stage biopharmaceutical company developing a fully human\nanti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other\nautoimmune diseases, today announced that members of its management team will\nparticipate in upcoming investor conferences in September:\n\nCiti Biopharma Back to School Conference \nDate: September 10, 2026\nTime: 11:20 - 11:55 a.m. ET\nFormat: Fireside Chat\n(https://www.globenewswire.com/Tracker?data=BGBQu798cqRhYVPhhVnNDqhUOW4x3UxaJeUmTItpRUoK34nsm-v2vmPBjcmEfasQ1Yy5GfocG8ff3keEKM5usUGYEQb7MCVI_XN8c-Wv-x3rbjPq9GxyLp5GK4PATuC72QxJgQUYzmFPFZD4wQH76Wis2vuT2ZTMMmfkaZq5zlD4IHXMEgpM8_piQ5ar9DKHwHqx-yyMSps3Uk0aihZD5bmM0jKRwDbmBLVaoKNsHeV45mz7380G4CFn4VzcrQVj6PmfRSTW8jtdCBzUKU4497vCMUAiYHeAxk8b4ZN4YzkI_3ASNrjKGBzuQdXlODJDrIZ6LbSnDG2cGI1dxSujU5OCTXEuh7jdyy-AUumPDOTYjddBxhNWCKoxsPwbkXkl8zm83gQuvElfLcEodVO9nA4QP_Nw4W1Z4PLM-Ttg_KZbMP6MoBDNvmV0woy76YlJiItrNELQHQxiQ1mTUnKCbJGFXm7rOV-6Z7hc6g8UbAYr8URIweg2eoSnjk3W8CBM)\n\nPresenter: Samuel J. Reich, Chief Executive Officer\nLocation: New York, NY\n\nMorgan Stanley 24th Annual Global Healthcare Conference\nDate: September 14, 2026\nFormat: One-on-one meetings \nLocation: New York, NY\n\nSAB BIO management will be available for one-on-one meetings during the\nconferences. Interested parties should contact their conference representative\nto arrange a meeting. To access replay webcasts of investor events, please\nvisit the Investors & Media\n(https://www.globenewswire.com/Tracker?data=RbxUZwUrhCXkAIh2LbZV4kv6wYxXt218U2Y1wSL6QhgIX9DzjST6miED0SvN0raGsFrr8tHksk7MrMeJOrgiebOiC2Z9SDGrUHwve9zZCdIiLDYqN323Nw6dWfrv0Yh2ujctDzB9Mr5028b8v86IvCgDJgM2UsvVFv7_1My7SMWFZyTvey8KSE7h5idDaEjhKEuF1-iVr2GlRQ-08n4GHSyJ_emJIO9FI56OGR2hQ_MET059VMwjplHDbt3IJ15juBIzija4yupnuOtk7B2k-g==) section\nof SAB BIO’s website at www.sab.bio.\n\nAbout SAB BIO\nSAB BIO is a clinical-stage biopharmaceutical company focused on developing\nmulti-specific, high-potency, human immunoglobulin G (hIgG) to treat and\nprevent immune and autoimmune disorders. Using advanced genetic engineering\nand antibody science, SAB BIO developed a proprietary technology which holds\nthe potential to generate additional novel therapeutic candidates utilizing\nthe human immune response, without the need for human donors or convalescent\nplasma. SAB BIO has optimized genetic engineering in the development of\ntranschromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug\ndevelopment production system is able to generate a diverse repertoire of\nspecifically targeted, high-potency, hIgGs that can address a wide range of\nserious unmet needs in human diseases. The Company’s lead candidate,\nSAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach\nthat aims to change the T1D treatment paradigm by delaying onset and\npotentially preventing disease progression of Stage 3 T1D patients. SAB-142 is\ncurrently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients\nin a registrational Phase 2b clinical trial called SAFEGUARD. For more\ninformation, visit www.sab.bio.\n\nCONTACTS\n\nInvestor Relations:\nChristine Ryan\nir@sab.bio\n\nMedia:\nSheila Carlson\nmedia@sab.bio\n\nThis press release was published by a CLEAR® Verified individual.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/6d99a771-f2c9-4d05-bf57-4f6c070df032)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9Rd6Vp","title":"SAB BIO to Participate in Upcoming Investor Conferences","author":"Globe Newswire","ticker":"SABS","created":"2026-09-01T12:30:00.637Z","tickers":["SABS","SABSW"],"exchange":"NASDAQ","article_body":"MIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:\nSABS\n(https://www.globenewswire.com/Tracker?data=gn9wlpBP8jVtZmDbRGypmYKJvtq6y1SPPPzWSZf7SJELoOqAJZAK-2vbrfKiPuTjI5M1VX8d569HzTmthbM8n8pUfznUJNSKZwW2LWH1mSQpEfj8lvby_V6cJ0taDVhXfs94rMC9ywfhBNY5eSJxkkPK7yZEccANfcZXUia1RJAE_ewrvVTKoecpq3EjYzUuEcpZIbGLLOscqVNYc46eo44c4M8eyqwSRyzbrrHwxVxoz6etCB5yC13-a-lHvE-3)),\na clinical-stage biopharmaceutical company developing a fully human\nanti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other\nautoimmune diseases, today announced that members of its management team will\nparticipate in upcoming investor conferences in September:\n\nCiti Biopharma Back to School Conference \nDate: September 10, 2026\nTime: 11:20 - 11:55 a.m. ET\nFormat: Fireside Chat\n(https://www.globenewswire.com/Tracker?data=BGBQu798cqRhYVPhhVnNDqhUOW4x3UxaJeUmTItpRUoK34nsm-v2vmPBjcmEfasQ1Yy5GfocG8ff3keEKM5usUGYEQb7MCVI_XN8c-Wv-x3rbjPq9GxyLp5GK4PATuC72QxJgQUYzmFPFZD4wQH76Wis2vuT2ZTMMmfkaZq5zlD4IHXMEgpM8_piQ5ar9DKHwHqx-yyMSps3Uk0aihZD5bmM0jKRwDbmBLVaoKNsHeV45mz7380G4CFn4VzcrQVj6PmfRSTW8jtdCBzUKU4497vCMUAiYHeAxk8b4ZN4YzkI_3ASNrjKGBzuQdXlODJDrIZ6LbSnDG2cGI1dxSujU5OCTXEuh7jdyy-AUumPDOTYjddBxhNWCKoxsPwbkXkl8zm83gQuvElfLcEodVO9nA4QP_Nw4W1Z4PLM-Ttg_KZbMP6MoBDNvmV0woy76YlJiItrNELQHQxiQ1mTUnKCbJGFXm7rOV-6Z7hc6g8UbAYr8URIweg2eoSnjk3W8CBM)\n\nPresenter: Samuel J. Reich, Chief Executive Officer\nLocation: New York, NY\n\nMorgan Stanley 24th Annual Global Healthcare Conference\nDate: September 14, 2026\nFormat: One-on-one meetings \nLocation: New York, NY\n\nSAB BIO management will be available for one-on-one meetings during the\nconferences. Interested parties should contact their conference representative\nto arrange a meeting. To access replay webcasts of investor events, please\nvisit the Investors & Media\n(https://www.globenewswire.com/Tracker?data=RbxUZwUrhCXkAIh2LbZV4kv6wYxXt218U2Y1wSL6QhgIX9DzjST6miED0SvN0raGsFrr8tHksk7MrMeJOrgiebOiC2Z9SDGrUHwve9zZCdIiLDYqN323Nw6dWfrv0Yh2ujctDzB9Mr5028b8v86IvCgDJgM2UsvVFv7_1My7SMWFZyTvey8KSE7h5idDaEjhKEuF1-iVr2GlRQ-08n4GHSyJ_emJIO9FI56OGR2hQ_MET059VMwjplHDbt3IJ15juBIzija4yupnuOtk7B2k-g==) section\nof SAB BIO’s website at www.sab.bio.\n\nAbout SAB BIO\nSAB BIO is a clinical-stage biopharmaceutical company focused on developing\nmulti-specific, high-potency, human immunoglobulin G (hIgG) to treat and\nprevent immune and autoimmune disorders. Using advanced genetic engineering\nand antibody science, SAB BIO developed a proprietary technology which holds\nthe potential to generate additional novel therapeutic candidates utilizing\nthe human immune response, without the need for human donors or convalescent\nplasma. SAB BIO has optimized genetic engineering in the development of\ntranschromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug\ndevelopment production system is able to generate a diverse repertoire of\nspecifically targeted, high-potency, hIgGs that can address a wide range of\nserious unmet needs in human diseases. The Company’s lead candidate,\nSAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach\nthat aims to change the T1D treatment paradigm by delaying onset and\npotentially preventing disease progression of Stage 3 T1D patients. SAB-142 is\ncurrently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients\nin a registrational Phase 2b clinical trial called SAFEGUARD. For more\ninformation, visit www.sab.bio.\n\nCONTACTS\n\nInvestor Relations:\nChristine Ryan\nir@sab.bio\n\nMedia:\nSheila Carlson\nmedia@sab.bio\n\nThis press release was published by a CLEAR® Verified individual.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/6d99a771-f2c9-4d05-bf57-4f6c070df032)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-01T12:30:00.683006739Z","server_sent_at_ms":1788265800683},"received_at":"2026-09-01T12:30:00.768Z","source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354153/0/en/sab-bio-to-participate-in-upcoming-investor-conferences.html"},"analysis":{"id":"121454","press_release_id":"132553","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"SAB Biotherapeutics announced that management will participate in the Citi Biopharma Back to School Conference on September 10 and the Morgan Stanley 24th Annual Global Healthcare Conference on September 14.\n\nCEO Samuel J. Reich is scheduled to present a fireside chat at the Citi event, while the company will conduct one-on-one meetings at the Morgan Stanley conference.\n\nSAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing immunoglobulins, with its lead candidate SAB-142 currently in a registrational Phase 2b trial for Type 1 Diabetes.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Non-material conference attendance update."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[{"name":"Samuel J. Reich","role":"Chief Executive Officer"},{"name":"Christine Ryan","role":"Investor Relations"},{"name":"Sheila Carlson","role":"Media Contact"}],"products":["SAB-142"],"companies":[{"name":"SAB Biotherapeutics, Inc.","ticker":"SABS"},{"name":"Citi","relationship":"conference host"},{"name":"Morgan Stanley","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement regarding management participation in upcoming investor conferences. No material financial, clinical, or strategic developments disclosed."},"tickerRelevance":{"others":[],"primary":"SABS"},"globalImportance":10,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"routine_conference_announcement"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"SAB Biotherapeutics announced that management will participate in the Citi Biopharma Back to School Conference on September 10 and the Morgan Stanley 24th Annual Global Healthcare Conference on September 14.\n\nCEO Samuel J. Reich is scheduled to present a fireside chat at the Citi event, while the company will conduct one-on-one meetings at the Morgan Stanley conference.\n\nSAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing immunoglobulins, with its lead candidate SAB-142 currently in a registrational Phase 2b trial for Type 1 Diabetes.","key_figures":null,"named_entities":{"people":[{"name":"Samuel J. Reich","role":"Chief Executive Officer"},{"name":"Christine Ryan","role":"Investor Relations"},{"name":"Sheila Carlson","role":"Media Contact"}],"products":["SAB-142"],"companies":[{"name":"SAB Biotherapeutics, Inc.","ticker":"SABS"},{"name":"Citi","relationship":"conference host"},{"name":"Morgan Stanley","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-01T14:15:36.527Z","global_importance":10,"audience_relevance":5,"importance_components":{"tickerTier":"micro-cap","eventGravity":"routine_conference_announcement"}},"durationMs":79493,"modelName":"glm-4.7"}}